Urokinase-type plasminogen activator receptor (uPAR), tissue factor (TF) and epidermal growth factor receptor (EGFR): tumor expression patterns and prognostic value in oral cancer

Christensen, Anders; Kiss, Katalin; Lelkaitis, Giedrius; Juhl, Karina; Persson, Morten; Charabi, Birgitte Wittenborg; Mortensen, Jann; Forman, Julie Lyng; Sørensen, Anne Lyngholm; Jensen, David Hebbelstrup; Kjaer, Andreas; von Buchwald, Christian

doi:10.1186/s12885-017-3563-3

Table 3 Uni- and multivariate analyses using Cox proportional hazards model for OS and DFS in relation to clinocopathological variables and biomarker expression for in 191 OSCC patients

From: Urokinase-type plasminogen activator receptor (uPAR), tissue factor (TF) and epidermal growth factor receptor (EGFR): tumor expression patterns and prognostic value in oral cancer

		Overall Survival (OS)						Disease Free Survival (DFS)
		Univariate analysis			Multivariate analysis			Univariate analysis			Multivariate analysis
Variable		p-value	HR	95% CI	p-value	HR	95% CI	p-value	HR	95% CI	p-Value	HR	95% CI
Gender	Men	0.745	1.075	0.696–1.658	0.260	1.320	0.814–2.140	0.576	1.121	0.751–1.673	0.147	1.386	0.891–2.155
Gender	Women
Age^b	−	0.027	1.019	1.002–1.037	0.002	1.034	1.012–1.056	0.017	1.019	1.003–1.035	0.005	1.027	1.008–1.047
Tobacco	Low	0.533	1.167	0.718–1.896	0.873	1.047	0.594–1.847	0.991	0.997	0.650–1.531	0.953	0.985	0.592–1.638
Tobacco	High
T-site	Tongue	0.355	1.211	0.807–1.818	0.786	0.935	0.577–1.516	0.885	1.028	0.708–1.491	0.200	0.743	0.472–1.170
T-site	FOM
Margins	Negative	<0.000	2.385	1.580–3.600	0.009	1.788	1.788–2.767	<0.000	2.457	1.681–3.590	0.000	2.126	1.418–3.189
Margins	Positive
T-stage	T1-T2	0.001	2.326	1.417–3.818	0.335	1.346	0.736–2.464	0.005	1.987	1.232–3.204	0.364	1.305	0.735–2.317
T-stage	T3-T4
N-stage	N0	<0.000	2.492	1.692–3.755	0.046	1.885	1.011–3.515	<0.000	2.220	1.512–3.259	0.047	1.814	1.008–3.263
N-stage	N+
ECS	No	0.000	0.310	0.172–0.560	0.118	0.551	0.262–1.262	<0.000	0.293	0.166–0.518	0.059	0.497	0.241–1.028
ECS	Yes
TNM stage	S1-S2	<0.000	2.606	1.721–3.945	0.889	1.052	0.515–2.149	0.000	2.115	1.428–3.133	0.930	0.971	0.501–1.882
TNM stage	S3-S4
Grade	G1-G2	0.104	0.606	0.330–1.109	0.084^a	0.676	0.353–1.293	0.084	1.639	0.935–2.874	0.115^a	0.613	0.340–1.104
	G3-G4
	G2
	G3		0.672	0.364–1.241					0.680	0.385–1.199
	G4	0.063	0.394	0.180–0.864		0.084	0.214–1.103	0.039	0.399	0.194–0.819		0.455	0.215–0.964
Radiotherapy	Yes	0.005	1.776	1.185–2.663	0.114	1.451	0.914–2.303	0.096	1.375	0.945–1.998	0.201	1.318	0.863–2.014
Radiotherapy	No
uPAR	High	0.031	1.595	1.044–2.439	0.128	1.435	0.901–2.287	0.145	1.351	0.902–2.025	0.326	1.246	0.803–1.931
uPAR	Low
TF	High	0.846	0.960	0.634–1.452	0.977	0.993	0.629–1.569	0.846	1.038	0.710–1.519	0.445	1.179	0.773–1.798
TF	Low
EGFR	High	0.813	0.952	0.630–1.437	0.922	1.023	0.654–1.599	0.329	0.826	0.563–1.212	0.219	0.766	0.501–1.172
EGFR	Low

Significant p-values of 0.05 or less are highlighted in bold. ^aGrade had multilevel specification and an overall p-value for the group-covariate was calculated in the multivariate analysis. ^bAge entered the analyses as a continuous variable

Back to article page

ISSN: 1471-2407

Contact us

Submission enquiries: bmccancer@biomedcentral.com
General enquiries: ORSupport@springernature.com

BMC Cancer

Contact us